Postnatal management of preterm infants with spinal muscular atrophy: experience from German newborn screening.
5q-SMA
Newborn screening
Nusinersen
Onasemnogene Abeparvovec
Preterm infants
Risdiplam
SMA treatment
Spinal muscular atrophy
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
26 Sep 2024
26 Sep 2024
Historique:
received:
11
06
2024
accepted:
11
09
2024
medline:
27
9
2024
pubmed:
27
9
2024
entrez:
26
9
2024
Statut:
epublish
Résumé
The introduction of newborn screening (NBS) for spinal muscular atrophy (SMA) has increased the early diagnosis of 5q-associated SMA in presymptomatic and symptomatic preterm infants. National and international recommendations for treating preterms and newborns < 38 weeks of gestational age are unavailable. Our retrospective multicentre study aimed to evaluate the postnatal clinical course of preterm infants with 5q-associated SMA diagnosed since the implementation of NBS in Germany in 2021 and to summarize the German experience regarding the decision-making process for available treatment regimens for preterm infants with ≤ 3 survival of motor neuron 2 (SMN2) copies. Twelve preterm infants with 5q-associated SMA and a mean gestational age of 34.0 weeks (range: 26.1-36.8) and birth weight of 2022 g (range: 645-3370) were reported from 8/20 German SMA NBS follow-up centers using a pseudonymized questionnaire. Confirmatory diagnosis, including SMN2 copy number, was completed on average on postnatal day 13. All patients had a biallelic deletion of exon 7 or exons 7 and 8 of the survival of motor neuron 1 (SMN1) gene, with SMN2 copy numbers of two in 10 patients and three in two patients. The neonatal course was complicated by respiratory distress due to prematurity (n = 2), sepsis (n = 2), and jaundice (n = 2). At birth, 11 preterm infants (91.6%) were presymptomatic. However, the neurological status of one patient deteriorated at five weeks of age (postconceptional age of 41.8 weeks) prior to the start of treatment. Disease-modifying treatments were initiated in all patients at a mean postconceptional age of 38.8 weeks, with the majority receiving onasemnogene abeparvovec (83.3%, including 2 patients with prior risdiplam bridge therapy). Notably, consensus among participating experts from German neuromuscular centers resulted in 83.3% of patients receiving disease-modifying treatment at term. Premature infants with SMA require interdisciplinary care in close collaboration with the neuromuscular center. SMA NBS facilitates early initiation of disease-modifying therapy, ideally during the presymptomatic phase, which significantly influences the prognosis of the newborn.
Sections du résumé
BACKGROUND
BACKGROUND
The introduction of newborn screening (NBS) for spinal muscular atrophy (SMA) has increased the early diagnosis of 5q-associated SMA in presymptomatic and symptomatic preterm infants. National and international recommendations for treating preterms and newborns < 38 weeks of gestational age are unavailable. Our retrospective multicentre study aimed to evaluate the postnatal clinical course of preterm infants with 5q-associated SMA diagnosed since the implementation of NBS in Germany in 2021 and to summarize the German experience regarding the decision-making process for available treatment regimens for preterm infants with ≤ 3 survival of motor neuron 2 (SMN2) copies.
RESULTS
RESULTS
Twelve preterm infants with 5q-associated SMA and a mean gestational age of 34.0 weeks (range: 26.1-36.8) and birth weight of 2022 g (range: 645-3370) were reported from 8/20 German SMA NBS follow-up centers using a pseudonymized questionnaire. Confirmatory diagnosis, including SMN2 copy number, was completed on average on postnatal day 13. All patients had a biallelic deletion of exon 7 or exons 7 and 8 of the survival of motor neuron 1 (SMN1) gene, with SMN2 copy numbers of two in 10 patients and three in two patients. The neonatal course was complicated by respiratory distress due to prematurity (n = 2), sepsis (n = 2), and jaundice (n = 2). At birth, 11 preterm infants (91.6%) were presymptomatic. However, the neurological status of one patient deteriorated at five weeks of age (postconceptional age of 41.8 weeks) prior to the start of treatment. Disease-modifying treatments were initiated in all patients at a mean postconceptional age of 38.8 weeks, with the majority receiving onasemnogene abeparvovec (83.3%, including 2 patients with prior risdiplam bridge therapy). Notably, consensus among participating experts from German neuromuscular centers resulted in 83.3% of patients receiving disease-modifying treatment at term.
CONCLUSIONS
CONCLUSIONS
Premature infants with SMA require interdisciplinary care in close collaboration with the neuromuscular center. SMA NBS facilitates early initiation of disease-modifying therapy, ideally during the presymptomatic phase, which significantly influences the prognosis of the newborn.
Identifiants
pubmed: 39327607
doi: 10.1186/s13023-024-03362-z
pii: 10.1186/s13023-024-03362-z
doi:
Substances chimiques
Survival of Motor Neuron 1 Protein
0
Survival of Motor Neuron 2 Protein
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
353Informations de copyright
© 2024. The Author(s).
Références
Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28:103–15. https://doi.org/10.1016/j.nmd.2017.11.005 .
doi: 10.1016/j.nmd.2017.11.005
pubmed: 29290580
Ramos DM, d’Ydewalle C, Gabbeta V, Dakka A, Klein SK, Norris DA, et al. Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment. J Clin Invest. 2019;129:4817–31. https://doi.org/10.1172/JCI124120 .
doi: 10.1172/JCI124120
pubmed: 31589162
pmcid: 6819103
Thelen MP, Kye MJ. The role of RNA binding proteins for local mRNA translation: implications in neurological disorders. Front Mol Biosci. 2020;6:161. https://doi.org/10.3389/fmolb.2019.00161 .
doi: 10.3389/fmolb.2019.00161
pubmed: 32010708
pmcid: 6974540
Day JW, Howell K, Place A, Long K, Rossello J, Kertesz N, Nomikos G. Advances and limitations for the treatment of spinal muscular atrophy. BMC Pediatr. 2022;22:632. https://doi.org/10.1186/s12887-022-03671-x .
doi: 10.1186/s12887-022-03671-x
pubmed: 36329412
pmcid: 9632131
Vill K, Kölbel H, Schwartz O, Blaschek A, Olgemöller B, Harms E, et al. One year of newborn screening for SMA – results of a German pilot project. J Neuromuscul Dis. 2019;6:503–15. https://doi.org/10.3233/JND-190428 .
doi: 10.3233/JND-190428
pubmed: 31594245
pmcid: 6918901
Masson R, Mazurkiewicz-Bełdzińska M, Rose K, Servais L, Xiong H, Zanoteli E, et al. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurol. 2022;21:1110–9. https://doi.org/10.1016/S1474-4422(22)00339-8 .
doi: 10.1016/S1474-4422(22)00339-8
pubmed: 36244364
De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29:842–56. https://doi.org/10.1016/j.nmd.2019.09.007 .
doi: 10.1016/j.nmd.2019.09.007
pubmed: 31704158
pmcid: 7127286
Shell RD, McGrattan KE, Hurst-Davis R, Young SD, Baranello G, Lavrov A, et al. Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial. Neuromuscul Disord. 2023;33:670–6. https://doi.org/10.1016/j.nmd.2023.06.005 .
doi: 10.1016/j.nmd.2023.06.005
pubmed: 37455203
Müller-Felber W, Blaschek A, Schwartz O, Gläser D, Nennstiel U, Brockow I, et al. Newbornscreening SMA – from pilot project to nationwide screening in Germany. J Neuromuscul Dis. 2023;10:55–65. https://doi.org/10.3233/JND-221577 .
doi: 10.3233/JND-221577
pubmed: 36463459
pmcid: 9881029
Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene Abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial. Nat Med. 2022;28:1381–9. https://doi.org/10.1038/s41591-022-01866-4 .
doi: 10.1038/s41591-022-01866-4
pubmed: 35715566
pmcid: 9205281
FDA. Full prescribing information ZOLGENSMA (revised 10/2023). US Food and Drug Administration. 2023. https://www.fda.gov/media/126109/download . Accessed 10 April 2024.
Kariyawasam DST, Russell JS, Wiley V, Alexander IE, Farrar MA. The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet Med. 2020;22:557–65. https://doi.org/10.1038/s41436-019-0673-0 .
doi: 10.1038/s41436-019-0673-0
pubmed: 31607747
Kölbel H, Modler L, Blaschek A, Schara-Schmidt U, Vill K, Schwartz O, et al. Parental burden and quality of life in 5q-SMA diagnosed by newborn screening. Child (Basel). 2022;9:1829. https://doi.org/10.3390/children9121829 .
doi: 10.3390/children9121829
Chiang J, Xiao L, Nigro E, St-Laurent A, Weinstock L, Law E, et al. Sleep disordered breathing in infants identified through newborn screening with spinal muscular atrophy. Sleep Med. 2023;111:161–9. https://doi.org/10.1016/j.sleep.2023.09.019 .
doi: 10.1016/j.sleep.2023.09.019
pubmed: 37778092
Nigro E, Grunebaum E, Kamath B, Licht C, Malcolmson C, Jeewa A, et al. Case report: a case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment. Front Neurol. 2023;14:1230889. https://doi.org/10.3389/fneur.2023.1230889 .
doi: 10.3389/fneur.2023.1230889
pubmed: 37780708
pmcid: 10539898
Ferrante L, Melendez-Zaidi A, Lindsey W, Lotze T. Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec-xioi in a premature neonate with type 1 spinal muscular atrophy. Muscle Nerve. 2022;66:E8–10. https://doi.org/10.1002/mus.27648 .
doi: 10.1002/mus.27648
pubmed: 35616550
Lee BH, Deng S, Chiriboga CA, Kay DM, Irumudomon O, Laureta E, et al. Newborn screening for spinal muscular atrophy in New York State: clinical outcomes from the first 3 years. Neurology. 2022;99:e1527–37. https://doi.org/10.1212/WNL.0000000000200986 .
doi: 10.1212/WNL.0000000000200986
pubmed: 35835557
pmcid: 9576300
Lee BH, Waldrop MA, Connolly AM, Ciafaloni E. Time is muscle: a recommendation for early treatment for preterm infants with spinal muscular atrophy. Muscle Nerve. 2021;64:153–5. https://doi.org/10.1002/mus.27261 .
doi: 10.1002/mus.27261
pubmed: 33959970
Groen EJN, Perenthaler E, Courtney NL, Jordan CY, Shorrock HK, van der Hoorn D, et al. Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy. Hum Mol Genet. 2018;27:2851–62. https://doi.org/10.1093/hmg/ddy195 .
doi: 10.1093/hmg/ddy195
pubmed: 29790918
pmcid: 6077828
Deng S, Lee BH, Ciafaloni E. Parent perceptions in choosing treatment for infants with spinal muscular atrophy diagnosed through newborn screening. J Child Neurol. 2022;37:43–9. https://doi.org/10.1177/08830738211040292 .
doi: 10.1177/08830738211040292
pubmed: 34753336
Jefferies AL. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Paediatr Child Health. 2012;17:573–4. https://doi.org/10.1093/pch/17.10.573 .
doi: 10.1093/pch/17.10.573
pubmed: 24294068
pmcid: 3549698
Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 2004;350:1304–13. https://doi.org/10.1056/NEJMoa032089 .
doi: 10.1056/NEJMoa032089
pubmed: 15044641
Lemyre B, Dunn M, Thebaud B. Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia in preterm infants. Paediatr Child Health. 2020;25:322–31. https://doi.org/10.1093/pch/pxaa073 .
doi: 10.1093/pch/pxaa073
pubmed: 32765169
pmcid: 7395322
Gaillard J, Gu AR, Neil Knierbein EE. Necrotizing enterocolitis following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Pediatr. 2023;260:113493. https://doi.org/10.1016/j.jpeds.2023.113493 .
doi: 10.1016/j.jpeds.2023.113493
pubmed: 37211209